Policy · 117th Congress
House report questions FDA’s approval of Alzheimer’s drug
A decision on accelerated approval is due by Jan. 6, and the company is simultaneously submitting data for full approval based on results from a Phase 3 trial.
Search Roll Call
Search the Roll Call archive by keyword, date, Congress, section, or tags.